These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32664922)

  • 1. Is it financially beneficial for hospitals to prevent nosocomial infections?
    Benenson S; Cohen MJ; Schwartz C; Revva M; Moses AE; Levin PD
    BMC Health Serv Res; 2020 Jul; 20(1):653. PubMed ID: 32664922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of fixed and variable hospital costs due to Clostridium difficile infection: institutional incentives and directions for future research.
    Ryan P; Skally M; Duffy F; Farrelly M; Gaughan L; Flood P; McFadden E; Fitzpatrick F
    J Hosp Infect; 2017 Apr; 95(4):415-420. PubMed ID: 28320542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review.
    Gabriel L; Beriot-Mathiot A
    J Hosp Infect; 2014 Sep; 88(1):12-21. PubMed ID: 24996516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of hospital-acquired infections on the patient-level reimbursement-cost relationship in a DRG-based hospital payment system.
    Kaier K; Wolkewitz M; Hehn P; Mutters NT; Heister T
    Int J Health Econ Manag; 2020 Mar; 20(1):1-11. PubMed ID: 31165960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Financial Incentives to Reduce Hospital-Acquired Infections Under Alternative Payment Arrangements.
    Cohen CC; Liu J; Cohen B; Larson EL; Glied S
    Infect Control Hosp Epidemiol; 2018 May; 39(5):509-515. PubMed ID: 29457583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attributable costs and length of stay of hospital-acquired
    Leal JR; Conly J; Weaver R; Wick J; Henderson EA; Manns B; Ronksley P
    Infect Control Hosp Epidemiol; 2019 Oct; 40(10):1135-1143. PubMed ID: 31342884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study.
    Zhang S; Palazuelos-Munoz S; Balsells EM; Nair H; Chit A; Kyaw MH
    BMC Infect Dis; 2016 Aug; 16(1):447. PubMed ID: 27562241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in Japan.
    Fukuda H; Yano T; Shimono N
    Pharmacoeconomics; 2018 Nov; 36(11):1367-1376. PubMed ID: 30022364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of healthcare-associated Clostridium difficile infection in a non-metropolitan setting.
    Bond SE; Boutlis CS; Yeo WW; Pratt WAB; Orr ME; Miyakis S
    J Hosp Infect; 2017 Apr; 95(4):387-393. PubMed ID: 28131640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of Clostridium difficile Infections in French Hospitals in 2014 From the National Health Insurance Perspective.
    Leblanc S; Blein C; Andremont A; Bandinelli PA; Galvain T
    Infect Control Hosp Epidemiol; 2017 Aug; 38(8):906-911. PubMed ID: 28756805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals.
    Le Monnier A; Duburcq A; Zahar JR; Corvec S; Guillard T; Cattoir V; Woerther PL; Fihman V; Lalande V; Jacquier H; Mizrahi A; Farfour E; Morand P; Marcadé G; Coulomb S; Torreton E; Fagnani F; Barbut F;
    J Hosp Infect; 2015 Oct; 91(2):117-22. PubMed ID: 26253518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study.
    Asensio A; Di Bella S; Lo Vecchio A; Grau S; Hart WM; Isidoro B; Scotto R; Petrosillo N; Watt M; Nazir J
    Int J Infect Dis; 2015 Jul; 36():31-8. PubMed ID: 26003403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of healthcare-associated infections to the Brazilian public Unified Health System in a tertiary-care teaching hospital: a matched case-control study.
    Osme SF; Almeida APS; Lemes MF; Barbosa WO; Arantes A; Mendes-Rodrigues C; Gontijo Filho PP; Ribas RM
    J Hosp Infect; 2020 Oct; 106(2):303-310. PubMed ID: 32693085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the burden of Clostridium difficile infections for hospitals.
    Hebbinckuys E; Marissal JP; Preda C; Leclercq V
    J Hosp Infect; 2018 Jan; 98(1):29-35. PubMed ID: 28890287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospital-acquired Clostridium difficile infection: an institutional costing analysis.
    Choi KB; Suh KN; Muldoon KA; Roth VR; Forster AJ
    J Hosp Infect; 2019 Jun; 102(2):141-147. PubMed ID: 30690051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas.
    Aitken SL; Joseph TB; Shah DN; Lasco TM; Palmer HR; DuPont HL; Xie Y; Garey KW
    PLoS One; 2014; 9(7):e102848. PubMed ID: 25057871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impact of Clostridium difficile infection in a multihospital cohort of academic health centers.
    Pakyz A; Carroll NV; Harpe SE; Oinonen M; Polk RE
    Pharmacotherapy; 2011 Jun; 31(6):546-51. PubMed ID: 21923438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attributable cost and length of stay for central line-associated bloodstream infections.
    Goudie A; Dynan L; Brady PW; Rettiganti M
    Pediatrics; 2014 Jun; 133(6):e1525-32. PubMed ID: 24799537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inter-Hospital Transfer Is an Independent Risk Factor for Hospital-Associated Infection.
    Gardner C; Rubinfeld I; Gupta AH; Johnson JL
    Surg Infect (Larchmt); 2024 Mar; 25(2):125-132. PubMed ID: 38117608
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.